Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147319 | 0.83 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL20147313 | 0.83 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL26077291 | 0.82 | PDE4A (0.39) | CHRM5CHRM3SMN1; SMN2PDE4APDE4B | |
| SCHEMBL20147370 | 0.80 | HRH3 (0.35) | CYP2D6 | |
| SCHEMBL20147368 | 0.80 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL20069058 | 0.79 | POLB (0.35) | CHRM5CHRM3SMN1; SMN2PDE4APDE4B | |
| SCHEMBL20147342 | 0.79 | BIRC2 (0.37) | — | |
| SCHEMBL20147315 | 0.79 | HTT (0.37) | SMN1; SMN2CYP2D6 | |
| SCHEMBL9690498 | 0.77 | RAD52 (0.38) | CHRM5CHRM3SMN1; SMN2PDE4APDE4B | |
| SCHEMBL20147385 | 0.76 | CYP2D6 (0.33) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CHRM5 2607/4885CHRM3 2379/4885SMN1; SMN2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.